Impact of Tocilizumab Therapy After Switching From Tumor Necrosis Factor (TNF) inhibitors - Prevention of Joint Damage by Tocilizumab in Patients with Inadequate Response to Anti-TNF Therapies

被引：0
|
作者：
Tanaka, Yoshiya [1 ]
Takeuchi, Tsutomu
Amano, Koichi [3 ]
Sato, Eri [4 ]
Nawata, Masao [5 ]
Nagasawa, Hayato [6 ]
Hoshi, Daisuke [7 ]
Saito, Kazuyoshi
Fukuyo, Shunsuke
Hanami, Kentaro [5 ]
Kameda, Hideto
Kurasawa, Takahiko [6 ]
Kaneko, Yuko [2 ]
Yamanaka, Hisashi [4 ]
机构：
[1] Univ Occupat & Environm Hlth, Fukuoka, Japan
[2] Keio Univ, Sch Med, Shinjuku Ku, Tokyo, Japan
[3] Saitama Med Univ, Saitama Med Ctr, Saitama, Japan
[4] Tokyo Womens Med Univ, Inst Rheumatol, Tokyo, Japan
[5] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka 807, Japan
[6] Saitama Med Ctr, Kawagoe, Saitama, Japan
[7] Tokyo Womens Med Univ, Tokyo, Japan
来源：
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1239
引用
收藏
页码：S484 / S484
页数：1
相关论文
共 50 条
  • [21] Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors
    Tanaka, Yoshiya
    Takeuchi, Tsutomu
    Amano, Koichi
    Saito, Kazuyoshi
    Hanami, Kentaro
    Nawata, Masao
    Fukuyo, Shunsuke
    Kameda, Hideto
    Kaneko, Yuko
    Kurasawa, Takahiko
    Nagasawa, Hayato
    Hoshi, Daisuke
    Sato, Eri
    Yamanaka, Hisashi
    MODERN RHEUMATOLOGY, 2014, 24 (03) : 399 - 404
  • [22] Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent
    Yamauchi, Paul S.
    Bissonnette, Robert
    Teixeira, Henrique D.
    Valdecantos, Wendell C.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 75 (03) : 612 - +
  • [23] TOCILIZUMAB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO DMARDS AND/OR TNF INHIBITORS: ACT-SURE PRELIMINARY RESULTS
    Tymms, K.
    Littlejohn, G.
    Bossingham, D.
    Griffiths, H.
    Bagga, H.
    Clemens, L.
    Smith, M.
    Bird, P.
    Bykerk, V
    INTERNAL MEDICINE JOURNAL, 2011, 41 : 18 - 18
  • [24] Tumor necrosis Factor (TNF) Bioactivity at the site of an acute cell-Mediated immune response is Preserved in rheumatoid arthritis Patients responding to anti-TNF Therapy
    Byng-Maddick, Rachel
    Turner, Carolin T.
    Pollara, Gabriele
    Ellis, Matthew
    Guppy, Naomi J.
    Bell, Lucy C. K.
    Ehrenstein, Michael R.
    Noursadeghi, Mahdad
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [25] Tumor necrosis factor (TNF) in inflammatory bowel disease: Gene polymorphisms, animal models, and potential for anti-TNF therapy
    Stokkers, PCF
    Camoglio, L
    vanDeventer, SJH
    JOURNAL OF INFLAMMATION, 1996, 47 (1-2) : 97 - 103
  • [26] Successful Switch of Patients with Rheumatoid Arthritis Developing Anti-tumor Necrosis Factor (anti-TNF)-induced Lupus to Another Anti-TNF Agent
    Ye, Carrie
    Sholter, Dalton
    Martin, Liam
    Keeling, Stephanie
    JOURNAL OF RHEUMATOLOGY, 2011, 38 (06) : 1216 - 1217
  • [27] Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs or anti-tumor necrosis factor
    Albattal, Basel M.
    ANNALS OF SAUDI MEDICINE, 2016, 36 (03) : 190 - 196
  • [28] Comparative Long-Term Effectiveness of Switching to Another Tumour Necrosis Factor Antagonists, Tocilizumab or Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to a First-Line TNF Inhibitor
    Faria, Daniela Santos
    Eusebio, Monica
    Silva, Ioana Leite
    Rodrigues, Joana Ramos
    Neves, Joana Sousa
    Duarte, Ana Catarina
    Lopes, Carina
    Valido, Ana
    Dinis, Joana
    Freitas, Joao
    Santiago, Mariana
    Ferreira, Raquel
    Ganhao, Sara
    Miranda, Luis Cunha
    Peixoto, Daniela
    Teixeira, Filipa
    Alcino, Sergio
    Afonso, Carmo
    Costa, Jose Tavares
    Santos, Maria Jose
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [29] Benefit of switching to a second anti-TNF therapy on HAQ response in rheumatoid arthritis patients with lack of response to their first anti-TNF therapy: Results from the BSR biologics register (BSRBR)
    Lunt, M.
    Hyrich, K. L.
    Watson, K. D.
    Dixon, W. G.
    Symmons, D. P.
    RHEUMATOLOGY, 2007, 46 : I16 - I16
  • [30] Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients
    Du Pan, Sophie Martin
    Scherer, Almut
    Gabay, Cem
    Finckh, Axel
    ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (06) : 997 - 999
12345